DRUG (Bright Minds Biosciences) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)


DRUG Bright Minds Biosciences Inc DRUG
34 GF Score
Price $65.79
! 2 Warning Signs
View Full Analysis

What is Bright Minds Biosciences LT-Debt-to-Total-Asset?

Bright Minds Biosciences DRUG +3.35% 34 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates DRUG with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bright Minds Biosciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Bright Minds Biosciences's long-term debt to total assets ratio declined from Mar. 2025 (0.00) to Mar. 2026 (0.00). It may suggest that Bright Minds Biosciences is progressively becoming less dependent on debt to grow their business.

Bright Minds Biosciences  (NAS:DRUG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bright Minds Biosciences LT-Debt-to-Total-Asset Related Terms

Bright Minds Biosciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Bright Minds Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bright Minds Biosciences LT-Debt-to-Total-Asset Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.01 0.00 0.01 0.00

Bright Minds Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DRUG
34GF Score
Bright Minds Biosciences Inc DRUG
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bright Minds Biosciences LT-Debt-to-Total-Asset Calculation

Bright Minds Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (A: Sep. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2025 )/Total Assets (A: Sep. 2025 )
=0.03/61.025
=

Bright Minds Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0/227.671
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Bright Minds Biosciences (DRUG) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bright Minds Biosciences and its competitors.
Is Bright Minds Biosciences' LT-Debt-to-Total-Asset too high?
Bright Minds Biosciences' current LT-Debt-to-Total-Asset is 0.00. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Bright Minds Biosciences' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bright Minds Biosciences and its competitors. Bright Minds Biosciences's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bright Minds Biosciences Business Description

Other Exchanges DRUG:Canada
Address 19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score

Get the complete analysis for DRUG

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.79
Price